Entecavir: a review of its use in the treatment of chronic hepatitis B in patients with decompensated liver disease. - Wikidata - wikimedia - TriplyDB

Entecavir: a review of its use in the treatment of chronic hepatitis B in patients with decompensated liver disease.

Entecavir: a review of its use in the treatment of chronic hepatitis B in patients with decompensated liver disease.

http://www.wikidata.org/entity/Q37964712

about

Prevention of hepatocellular carcinoma in patients with chronic hepatitis B Entecavir for Patients with Hepatitis B Decompensated Cirrhosis in China: a meta-analysis.Multiple Drug Transporters Are Involved in Renal Secretion of Entecavir.Adverse effects of oral antiviral therapy in chronic hepatitis B.Electrolyte and Acid-Base Disturbances in End-Stage Liver Disease: A Physiopathological Approach.Is increasing the dose of Entecavir effective in partial virological responders?Seroconversion of hepatitis B virus surface antigen in chronic hepatitis B child treated with entecavir.Treatment of hepatitis B virus cirrhosis

P2860

Q27023997-2F978824-C8A5-4DC1-A376-5DE4FDF45ABD Q37236357-3EE039C7-0BBD-4D0E-AD94-B842F94B9DA7 Q37287773-19A7BD61-3199-4E33-8F46-2A771EB58ACE Q37651892-6618B7FA-D406-45E7-BAF9-15D8BCE29148 Q39304722-69296391-5A12-4803-B32E-6D189F2FDF49 Q40385406-B48B90C5-49FD-4DC0-B838-82E055F8F3F3 Q41879601-E563D305-2CE5-43D3-948E-281181E01A4D Q42224748-A79F44BB-9ED4-44E8-AC21-8906358DDB03

P2860

Entecavir: a review of its use in the treatment of chronic hepatitis B in patients with decompensated liver disease.

http://www.wikidata.org/entity/Q37964712

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Entecavir: a review of its use ...... h decompensated liver disease.

@en

Entecavir: a review of its use ...... h decompensated liver disease.

@nl

type

label

Entecavir: a review of its use ...... h decompensated liver disease.

@en

Entecavir: a review of its use ...... h decompensated liver disease.

@nl

prefLabel

Entecavir: a review of its use ...... h decompensated liver disease.

@en

Entecavir: a review of its use ...... h decompensated liver disease.

@nl

P1433

Q37964712-D29849CA-1618-4F6B-ABD6-4C56AE1CB03C

P1476

Q37964712-DC30E8C9-DFCC-4ACC-A05B-79160172445E

P2860

Q37964712-00E18A2B-50D2-42B0-B2CC-AE70181EF65D

Q37964712-0F584166-6A93-4662-A354-FAE9013E1928

Q37964712-14985D35-DC23-405A-B0A9-89EC7E3465D8

Q37964712-17D68BA7-2F54-4515-88BB-A40B13E4BA10

Q37964712-18DBD691-4A08-4A7A-99E6-590073346886

Q37964712-24928B87-9E6D-481D-B651-864115B247DC

Q37964712-2B73E995-D9C5-4A22-94AD-160AFAC2C1D9

Q37964712-313197C1-5F9D-4F8A-AA17-DF76D005EAEC

Q37964712-3329D42E-F929-4AF7-8BDA-9F5F7D2FB7AC

Q37964712-3D85E2EA-83D1-4F70-BCD9-68EDA9770907

P2888

Q37964712-BE26449A-775E-4A4A-A423-BA1AC5E38314

P304

Q37964712-5E8A1191-3EB1-46EF-A5CD-DB67D00D9ED4

P31

Q37964712-C3A5BD4B-BCEE-44ED-99EF-9B6AEEF6A5D8

P356

Q37964712-B42271F0-DC8D-415B-B181-EE1222B235D3

P433

Q37964712-1790A4F4-629D-47A4-8997-E5A40CB6C0FC

P478

Q37964712-E57390BB-3052-4C6A-A286-1B3B32830F7E

P50

Q37964712-91F498AF-BA66-4CFC-A814-AC115B353559

P577

Q37964712-BAD660BC-8785-4A07-B8D1-7F5A9AAB78AC

P6179

Q37964712-BC0AEFDD-2D06-481B-9D15-A28F0FE2611F

P698

Q37964712-EEFE9C15-7975-45D8-BD05-F1F32687EF56

P356

11208510-000000000-00000

P1433

P1476

Entecavir: a review of its use ...... h decompensated liver disease.

@en

P2860

Mechanistic characterization and molecular modeling of hepatitis B virus polymerase resistance to entecavir

Two-year assessment of entecavir resistance in Lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions present

Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy.

Genotypic determinants and phenotypic properties of antiviral-resistant HBV variants: insight from entecavir resistance studies.

Mechanism of entecavir resistance of hepatitis B virus with viral breakthrough as determined by long-term clinical assessment and molecular docking simulation.

Early viral kinetics of telbivudine and entecavir: results of a 12-week randomized exploratory study with patients with HBeAg-positive chronic hepatitis B

The natural history of chronic HBV infection and geographical differences.

Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B.

The HBV drug entecavir - effects on HIV-1 replication and resistance

A comparison of 48-week treatment efficacy between clevudine and entecavir in treatment-naïve patients with chronic hepatitis B.

P2888

11208510-000000000-00000

P304

2511-2529

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2165/11208510-000000000-00000

http://www.w3.org/2001/XMLSchema#string

P433

18

http://www.w3.org/2001/XMLSchema#string

P478

71

http://www.w3.org/2001/XMLSchema#string

P50

Gillian M Keating

P577

2011-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1024806845

http://www.w3.org/2001/XMLSchema#string

P698

22141390

http://www.w3.org/2001/XMLSchema#string